A Phase 1b Trial of Ivosidenib Combined with Ruxolitinib in IDH1-Mutated Advanced-Phase MPNs

Protocol No

UCHICAGO-IRB23-1681

Staff Member

Laura Michaelis

Phase

I

Summary

By doing this study, we hope to learn about the safety of combining the JAK inhibitor ruxolitinib with the IDH1 inhibitor ivosidenib in IDH1-mutated, advanced-phase, Ph-negative
myeloproliferative neoplasms. The purpose of this research is to gather information on the safety and effectiveness of ruxolitinib in combination with ivosidenib.

Objective

This project is being done to learn about the safety of combining the JAK inhibitor
ruxolitinib with the IDH1 inhibitor ivosidenib in IDH1-mutated, advanced-phase, Ph-negative myeloproliferative neoplasms.

Status

OPEN TO ACCRUAL